Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study

被引:127
作者
Zanchetti, A
Hansson, L
Dahlöf, B
Elmfeldt, D
Kjeldsen, S
Kolloch, R
Larochelle, P
McInnes, GT
Mallion, JM
Ruilope, L
Wedel, H
机构
[1] Univ Milan, Osped Maggiore, Ctr Fisiol Clin & Ipertens, I-20122 Milan, Italy
[2] Ist Auxol Italiano, Milan, Italy
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden
[4] Univ Gothenburg, Ostra Hosp, Clin Trial Unit, Gothenburg, Sweden
[5] AstraZeneca R&D, Molndal, Sweden
[6] Univ Oslo, Ullevaal Hosp, Dept Cardiol, N-0407 Oslo, Norway
[7] Univ Munster, Krankenanstalten Gilead, Med Klin, Bielefeld, Germany
[8] Hop Hotel Dieu, Ctr Rech, Montreal, PQ, Canada
[9] Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland
[10] Univ Grenoble, Hop A Michallon, Grenoble, France
[11] Hosp 12 Octubre, Hypertens Unit, E-28041 Madrid, Spain
[12] Nord Sch Publ Hlth, Gothenburg, Sweden
关键词
age; antihypertensive treatment; cardiovascular risk factors; diabetes; gender; HOT Study; hypercreatininaemia; hypercholesterolaemia; ischaemic heart disease; smoking;
D O I
10.1097/00004872-200106000-00021
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background The Hypertension Optimal Treatment (HOT) Study has provided information about cardiovascular events in 18 790 hypertensives, subjected to pronounced blood pressure (BP) lowering for a mean of 3.8 years. The HOT study data have subsequently been analysed after stratification of the patients according to global cardiovascular risk, and it has been found that, despite intensive blood pressure lowering in all risk strata, morbid event rates increased with increasing risk stratum. Objectives Previously analysed global risk strata were based on combinations of risk factors. The analyses presented here were intended to provide information on the relative role that the presence of each individual factor may have in increasing cardiovascular risk, despite good BP control. Methods Risk ratios (RR) for patients with and those without a risk factor were calculated with 95% confidence intervals (CI) using a Cox proportional hazard model, and adjusted for all variables except the one under examination. Results For all risk factors considered and for all types of event, RR were always greater than 1, indicating a greater risk in the presence, compared with that in the absence of each factor. The male gender was a statistically significant risk for cardiovascular (CV) events, CV and total mortality and particularly for myocardial infarction (MI); age greater than or equal to 65 years for CV events, stroke, CV and particularly total mortality; smoking for all events analysed, but particularly for total mortality (twice higher in smokers than in non-smokers); high serum cholesterol (> 6.8 mmol/l) for CV events, MI and CV mortality; high serum creatinine (> 155 mu mol/l) for CV events, stroke, CV and total mortality; diabetes for CV events, stroke, total mortality and particularly CV mortality; and ischaemic heart disease for all events analysed. Adjusted RR were often close to or greater than 2. Conclusions Each of the risk factors considered was found to be an important cause of residual risk, despite good BP control. These findings emphasize the importance of addressing other correctable risk factors, e.g. smoking, hypercholesterolaemia and diabetes, as well as rigorous control of blood pressure, and of initiating antihypertensive therapy before cardiovascular and renal damage becomes manifest. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1149 / 1159
页数:11
相关论文
共 17 条
[1]   Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :761-769
[2]  
[Anonymous], 1982, NEW ENGL J MED, V307, P976
[3]  
[Anonymous], 1979, JAMA
[4]  
[Anonymous], HYPERTENSION S1
[5]  
[Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633
[6]  
[Anonymous], 1999, CIRCULATION
[7]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[8]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[9]   Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [J].
Curb, JD ;
Pressel, SL ;
Cutler, JA ;
Savage, PJ ;
Applegate, WB ;
Black, H ;
Camel, G ;
Davis, BR ;
Frost, PH ;
Gonzalez, N ;
Guthrie, G ;
Oberman, A ;
Rutan, GH ;
Stamler, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1886-1892
[10]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762